$TXMD
TherapeuticsMD, Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022011525 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q1
Revenue $18.68M $25.41M $19.87M
YoY Change -17.27% 31.35% 62.16%
Cost Of Revenue $4.737M $5.282M $4.690M
YoY Change -15.11% 61.09% 72.43%
Gross Profit $13.94M $20.12M $15.18M
YoY Change -17.98% 25.28% 59.18%
Gross Profit Margin 74.64% 79.21% 76.41%
Selling, General & Admin $47.91M $58.44M $42.41M
YoY Change -2.12% 49.81% -25.51%
% of Gross Profit 343.68% 290.4% 279.38%
Research & Development $1.420M $1.605M $2.050M
YoY Change -40.59% -20.82% -37.31%
% of Gross Profit 10.19% 7.98% 13.51%
Depreciation & Amortization $1.002M $200.0K $200.0K
YoY Change 285.38% 0.0% -23.08%
% of Gross Profit 7.19% 0.99% 1.32%
Operating Expenses $49.33M $60.05M $44.46M
YoY Change -4.39% 46.32% -26.46%
Operating Profit -$35.39M -$39.92M -$29.28M
YoY Change 2.27% 59.85% -42.5%
Interest Expense -$7.576M $7.518M $10.23M
YoY Change -0.45% -2.11% -263.37%
% of Operating Profit
Other Income/Expense, Net $8.000K $19.00K -$10.11M
YoY Change -93.85% -100.25% -3072.06%
Pretax Income -$42.96M -$47.42M -$39.38M
YoY Change 2.07% 45.41% -30.72%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$42.96M -$47.42M -$39.38M
YoY Change 2.07% 45.41% -30.72%
Net Earnings / Revenue -230.0% -186.65% -198.24%
Basic Earnings Per Share -$5.62
Diluted Earnings Per Share -$5.023M -$5.616M -$113.4K
COMMON SHARES
Basic Shares Outstanding 422.2M 6.945M
Diluted Shares Outstanding 8.444M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $65.12M $104.8M $137.6M
YoY Change -19.1% 31.71% -19.11%
Cash & Equivalents $65.12M $104.8M $137.6M
Short-Term Investments
Other Short-Term Assets $10.55M $10.37M $8.400M
YoY Change 40.64% 17.89% 27.27%
Inventory $7.622M $7.362M $7.300M
Prepaid Expenses
Receivables $36.18M $37.40M $33.70M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $119.5M $160.0M $187.0M
YoY Change -6.96% 30.7% -11.79%
LONG-TERM ASSETS
Property, Plant & Equipment $1.199M $1.388M $11.00M
YoY Change -38.26% -88.34% -9.09%
Goodwill
YoY Change
Intangibles $40.32M $39.62M
YoY Change -2.72%
Long-Term Investments
YoY Change
Other Assets $253.0K $253.0K $300.0K
YoY Change 0.0% -36.75% -40.0%
Total Long-Term Assets $50.00M $49.65M $52.30M
YoY Change -6.02% -9.56% -7.6%
TOTAL ASSETS
Total Short-Term Assets $119.5M $160.0M $187.0M
Total Long-Term Assets $50.00M $49.65M $52.30M
Total Assets $169.5M $209.6M $239.3M
YoY Change -6.68% 18.23% -10.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.32M $19.59M $10.30M
YoY Change -3.56% 21.69% -64.11%
Accrued Expenses $40.69M $47.05M $41.70M
YoY Change 41.28% 127.29% 127.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $188.3M $15.00M $5.000M
YoY Change
Total Short-Term Liabilities $252.9M $86.27M $61.30M
YoY Change 326.91% 82.38% -0.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $171.7M $179.0M
YoY Change -100.0% -27.57% -26.46%
Other Long-Term Liabilities $2.139M $8.984M $8.500M
YoY Change -75.41% 0.94% -3.41%
Total Long-Term Liabilities $2.139M $171.7M $187.5M
YoY Change -99.1% -30.19% -25.65%
TOTAL LIABILITIES
Total Short-Term Liabilities $252.9M $86.27M $61.30M
Total Long-Term Liabilities $2.139M $171.7M $187.5M
Total Liabilities $263.1M $267.0M $248.8M
YoY Change -13.91% -8.97% -20.71%
SHAREHOLDERS EQUITY
Retained Earnings -$1.051B
YoY Change 19.62%
Common Stock $957.7M
YoY Change 26.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$93.62M -$57.36M -$9.478M
YoY Change
Total Liabilities & Shareholders Equity $169.5M $209.6M $239.3M
YoY Change -6.68% 18.23% -10.91%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q1
OPERATING ACTIVITIES
Net Income -$42.96M -$47.42M -$39.38M
YoY Change 2.07% 45.41% -30.72%
Depreciation, Depletion And Amortization $1.002M $200.0K $200.0K
YoY Change 285.38% 0.0% -23.08%
Cash From Operating Activities -$39.56M -$38.22M -$38.38M
YoY Change 30.47% 12.26% -1.87%
INVESTING ACTIVITIES
Capital Expenditures -$1.514M -$182.0K $63.00K
YoY Change 202.8% -30.0% -114.32%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$1.514M -$182.0K -$438.0K
YoY Change 185.66% -30.0% -0.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $150.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.353M 31.82M 95.95M
YoY Change -95.73% 31722.0% 96.54%
NET CHANGE
Cash From Operating Activities -39.56M -38.22M -38.38M
Cash From Investing Activities -1.514M -182.0K -438.0K
Cash From Financing Activities 1.353M 31.82M 95.95M
Net Change In Cash -39.72M -6.583M 57.13M
YoY Change -4772.82% -80.76% 516.3%
FREE CASH FLOW
Cash From Operating Activities -$39.56M -$38.22M -$38.38M
Capital Expenditures -$1.514M -$182.0K $63.00K
Free Cash Flow -$38.04M -$38.04M -$38.44M
YoY Change 27.58% 12.58% -0.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M12D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y9M18D
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Liabilities
Liabilities
263093000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.therapeuticsmd.com/20211231#AccruedExpensesAndOtherCurrentLiabilities
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.therapeuticsmd.com/20211231#AccruedExpensesAndOtherCurrentLiabilities
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1334000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1118000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36176000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32382000
CY2021Q4 us-gaap Inventory Net
InventoryNet
7622000
CY2020Q4 us-gaap Inventory Net
InventoryNet
7993000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10548000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7543000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
119468000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
128404000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1199000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1942000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40318000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41445000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8234000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9566000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
44304000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
38170000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
252891000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
59238000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
237698000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
429886000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
429886000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
299765000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
299765000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
430000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
957309000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1051360000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
169472000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-10058000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-32645000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-172415000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-183524000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
275649000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-183524000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-176145000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
397992000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
246353000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-183524000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-176145000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-172415000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-183524000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-176145000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
109000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10682000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-176145000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
9201000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7668000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10679000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-183524000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-124001000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
184115000
CY2021 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
278000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
233000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18125000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-176145000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4093000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4067000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1392000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
533000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
238000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
318000
CY2021 txmd Inventory Charge
InventoryCharge
1082000
CY2020 txmd Inventory Charge
InventoryCharge
7205000
CY2021 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
5689000
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
79000
CY2020 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
2532000
CY2019 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
856000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
18125000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3337000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8593000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
10679000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
10682000
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1132000
CY2019 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-10058000
CY2021 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
720000
CY2020 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1541000
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
1074000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4327000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8224000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13651000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
711000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3005000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3209000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1734000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-750000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1887000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3563000
CY2021 txmd Increasedecrease In Accrued Expenses And Other Current Liabilities
IncreasedecreaseInAccruedExpensesAndOtherCurrentLiabilities
6134000
CY2020 txmd Increasedecrease In Accrued Expenses And Other Current Liabilities
IncreasedecreaseInAccruedExpensesAndOtherCurrentLiabilities
2904000
CY2019 txmd Increasedecrease In Accrued Expenses And Other Current Liabilities
IncreasedecreaseInAccruedExpensesAndOtherCurrentLiabilities
13675000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2139000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
220000
CY2019 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-166000
CY2021 txmd Adjustments To Reconcile Net Profit Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetProfitLossToCashProvidedByUsedInOperatingActivities
-29722000
CY2020 txmd Adjustments To Reconcile Net Profit Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetProfitLossToCashProvidedByUsedInOperatingActivities
-24053000
CY2019 txmd Adjustments To Reconcile Net Profit Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetProfitLossToCashProvidedByUsedInOperatingActivities
-10427000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-142693000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159471000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-165718000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2189000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1391000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1442000
CY2019 txmd Payment For Intellectual Property License
PaymentForIntellectualPropertyLicense
20000000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2450000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2223000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1598000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23892000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
184115000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
31703000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
77031000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
322000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
272000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
109000
CY2021 txmd Proceeds From Sale Of Common Stock Related To Employee Stock Purchase Plan
ProceedsFromSaleOfCommonStockRelatedToEmployeeStockPurchasePlan
233000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
50000000
CY2019 us-gaap Repayments Of Debt
RepaymentsOfDebt
81661000
CY2020 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
50000000
CY2019 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
200000000
CY2021 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5118000
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1250000
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
6652000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129552000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80725000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
188827000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-15364000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-80344000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80486000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160830000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
25849000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
17788000
CY2020 txmd Warrants Issued In Relation To Debt Financing Agreement
WarrantsIssuedInRelationToDebtFinancingAgreement
7668000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172400000
CY2021 txmd Current Liabilities Over Current Assets During Period
CurrentLiabilitiesOverCurrentAssetsDuringPeriod
133400000
CY2021 txmd Liabilities Over Assets During Period
LiabilitiesOverAssetsDuringPeriod
93600000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">C.</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Estimates and assumptions</p></td></tr></table></div> <p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity to U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We evaluate our estimated assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</p>
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1741000
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2019 txmd Inventory Charge
InventoryCharge
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1199000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2731000
CY2021 txmd License Rights Cost Amortized Expiration Period
LicenseRightsCostAmortizedExpirationPeriod
2039-06
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 txmd Number Of Geographic Location
NumberOfGeographicLocation
1
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1118000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
904000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
597000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
533000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
238000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
318000
CY2021 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
317000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
24000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
11000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1334000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1118000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
904000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3042000
CY2020Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
3748000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1642000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
895000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2938000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3350000
CY2021Q4 us-gaap Inventory Net
InventoryNet
7622000
CY2020Q4 us-gaap Inventory Net
InventoryNet
7993000
CY2021 txmd Inventory Charge
InventoryCharge
1100000
CY2020 txmd Inventory Charge
InventoryCharge
7200000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2568000
CY2021Q4 txmd Paragraph Four Legal Proceeding Costs
ParagraphFourLegalProceedingCosts
2304000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5513000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
4975000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10548000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7543000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3717000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3683000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2518000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1942000
CY2021 us-gaap Depreciation
Depreciation
800000
CY2020 us-gaap Depreciation
Depreciation
800000
CY2019 us-gaap Depreciation
Depreciation
400000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
47854000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
39986000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45674000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4552000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
41122000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
48186000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7868000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
40318000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
45997000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4552000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41445000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3451000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3445000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3447000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3445000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3445000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
20733000
CY2021Q4 txmd Finite Lived Intangible Assets Amortization Expense Net
FiniteLivedIntangibleAssetsAmortizationExpenseNet
37966000
CY2021 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2020 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1100000
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
100000
CY2021Q4 txmd Accrued Payroll And Related Costs
AccruedPayrollAndRelatedCosts
13764000
CY2020Q4 txmd Accrued Payroll And Related Costs
AccruedPayrollAndRelatedCosts
11179000
CY2021Q4 txmd Accrued Rebates Current
AccruedRebatesCurrent
11010000
CY2020Q4 txmd Accrued Selling And Marketing Expenses
AccruedSellingAndMarketingExpenses
228000
CY2021Q4 txmd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1995000
CY2020Q4 txmd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
925000
CY2021Q4 txmd Accrued Wholesale Distributor Fees
AccruedWholesaleDistributorFees
3614000
CY2020Q4 txmd Accrued Wholesale Distributor Fees
AccruedWholesaleDistributorFees
2632000
CY2020Q4 txmd Accrued Rebates Current
AccruedRebatesCurrent
11011000
CY2021Q4 txmd Accrued Sales Returns Reserve And Coupons Current
AccruedSalesReturnsReserveAndCouponsCurrent
2422000
CY2020Q4 txmd Accrued Sales Returns Reserve And Coupons Current
AccruedSalesReturnsReserveAndCouponsCurrent
7057000
CY2021Q4 txmd Accrued Selling And Marketing Expenses
AccruedSellingAndMarketingExpenses
2850000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
188269000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2571000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
925000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1361000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2254000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4717000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1959000
CY2021Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
44304000
CY2020Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
38170000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
39700000
CY2020 us-gaap Advertising Expense
AdvertisingExpense
35800000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
9000000.0
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
11731000
CY2020Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
12302000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
237698000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
188269000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
237698000
CY2021Q4 txmd Future Prepayment Fee Obligations
FuturePrepaymentFeeObligations
2200000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
11700000
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
22568000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
26049000
CY2021 txmd Debt Interest Prepayment Fee
DebtInterestPrepaymentFee
4660000
CY2021 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
5689000
CY2020 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
2532000
CY2019 us-gaap Debt Related Commitment Fees And Debt Issuance Costs
DebtRelatedCommitmentFeesAndDebtIssuanceCosts
856000
CY2021 us-gaap Interest Expense
InterestExpense
32917000
CY2020 us-gaap Interest Expense
InterestExpense
28581000
CY2019 us-gaap Interest Expense
InterestExpense
17382000
CY2018Q4 txmd Net Rentable Area Lease
NetRentableAreaLease
56212
CY2018Q4 txmd Rented Area Lease
RentedAreaLease
7561
CY2019Q3 txmd Additional Area Of Lease Occupied
AdditionalAreaOfLeaseOccupied
48651
CY2019Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P11Y
CY2021Q4 txmd Lessee Operating Lease Existence Of Option To Extend Number
LesseeOperatingLeaseExistenceOfOptionToExtendNumber
2
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q2 txmd Additional Area Of Lease Occupied
AdditionalAreaOfLeaseOccupied
6536
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
2100000
CY2021 us-gaap Variable Lease Payment
VariableLeasePayment
700000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
2300000
CY2020 us-gaap Variable Lease Payment
VariableLeasePayment
400000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
1600000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1413000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1443000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1477000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1513000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1551000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
5883000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
13280000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3856000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
9424000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8234000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9566000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1361000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2254000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8063000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8675000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
9424000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
10929000
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.083
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2335000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1618000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
999000
CY2021Q3 txmd Number Of Senior Executives Agreed For Separation Excluding Former Evp And Former Ceo
NumberOfSeniorExecutivesAgreedForSeparationExcludingFormerEVPAndFormerCEO
3
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2021 txmd Defined Contribution Plan Maximum Employer Matching Contribution
DefinedContributionPlanMaximumEmployerMatchingContribution
2000
CY2021 txmd Defined Contribution Plan Vesting Service Period
DefinedContributionPlanVestingServicePeriod
P5Y
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
4752116
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
42925277
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
  (1) The number of PSUs represents the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and 11,687,530 depending on the Company’s achievement of certain performance goals.   (2) The number of remaining shares of common stock available for future issuance is based on an assumption that the maximum performance goals for PSUs were achieved, where applicable.   (3) As of December 31, 2021, outstanding options have exercise prices ranging from $1.07 to $2.73 and will expire between January 2022 and June 2030. Unvested RSUs will vest between January 2022 and December 2024. If and when certain performance goals are achieved, then unvested PSUs will vest between June 2022 and March 2024.   (4) As of December 31, 2021, outstanding options have exercise prices ranging from $2.55 to $8.92 and will expire between March 2022 and February 2029.   (5) As of December 31, 2021, outstanding options have exercise prices ranging from $1.80 to $8.92 and will expire between January 2022 and February 2029.   (6) As of December 31, 2021, unvested RSUs will vest between August 2022 and October 2024 and unvested PSUs upon achievement of certain performance goals will vest between October 15, 2022 and August 2024.
CY2021Q3 txmd Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Eligible Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceEligibleOptions
5.01
CY2021Q3 txmd Number Of Eligible Employees Elected To Exchange Eligible Options
NumberOfEligibleEmployeesElectedToExchangeEligibleOptions
69
CY2021Q3 txmd Share Based Compensation Arrangement By Share Based Payment Options Granted To Purchase Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentOptionsGrantedToPurchaseCommonStock
4493000
CY2021Q3 txmd Percentage Of Shares Of Common Stock Underlying Eligible Options
PercentageOfSharesOfCommonStockUnderlyingEligibleOptions
0.915
CY2021Q3 txmd Number Of Annual Installments Vest
NumberOfAnnualInstallmentsVest
3
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20873000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.93
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12240000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
16069000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.61
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
12240000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4620000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.10
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
344000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.32
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1427000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
93000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.16
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
26000
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
5.57
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
25030000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.65
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3668000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
18026000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.88
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3320000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
737000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.58
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1182000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.23
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1739000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
416000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.80
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
387000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.76
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23782000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.80
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
152000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
19863000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.06
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
117000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
60000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.21
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
111000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.03
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
61000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5048000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.01
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1028000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.02
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
17655000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.52
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
16776000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.62
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18100000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10700000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10700000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16200000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2021Q4 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year One
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearOne
8646000
CY2021Q4 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Two
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearTwo
5199000
CY2021Q4 txmd Share Based Payment Arrangement Nonvested Award Option Cost Not Yet Recognized Year Three
ShareBasedPaymentArrangementNonvestedAwardOptionCostNotYetRecognizedYearThree
2355000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16200000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
86951000
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
64872000
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
49647000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
186000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-172415000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-183524000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-176145000
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
885100000
CY2021 txmd Net Operating Loss Carryforwards Term
NetOperatingLossCarryforwardsTerm
P20Y
CY2021 txmd Net Operating Loss Carryforwards Expiration Year
NetOperatingLossCarryforwardsExpirationYear
2031
CY2021 txmd Percentage Of Future Taxable Income
PercentageOfFutureTaxableIncome
0.80
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.051
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.040
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.221
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.270
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.225
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.015
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.021
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.008
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.027
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
224660000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
195008000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
17698000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
17252000
CY2021Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
20391000
CY2020Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
12992000
CY2021Q4 txmd Deferred Tax Asset Accrual For Sales Returns And Coupons
DeferredTaxAssetAccrualForSalesReturnsAndCoupons
3779000
CY2020Q4 txmd Deferred Tax Asset Accrual For Sales Returns And Coupons
DeferredTaxAssetAccrualForSalesReturnsAndCoupons
5060000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
186000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1674000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-241000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
268388000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
230257000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
268388000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
230257000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-172415000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-183524000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-176145000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
397992000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
275649000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
246353000
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
397992000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
275649000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
246353000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44569000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39782000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28103000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19866000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
23001000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25406000
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18678000
CY2021Q1 us-gaap Gross Profit
GrossProfit
15179000
CY2021Q2 us-gaap Gross Profit
GrossProfit
18869000
CY2021Q3 us-gaap Gross Profit
GrossProfit
20124000
CY2021Q4 us-gaap Gross Profit
GrossProfit
13941000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-29278000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35179000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39921000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-35392000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-39383000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-42652000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47420000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-42960000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2021Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12251000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10701000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19342000
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22578000
CY2020Q1 us-gaap Gross Profit
GrossProfit
9536000
CY2020Q2 us-gaap Gross Profit
GrossProfit
6301000
CY2020Q3 us-gaap Gross Profit
GrossProfit
16063000
CY2020Q4 us-gaap Gross Profit
GrossProfit
16997000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-50922000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-45038000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24974000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-34607000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-56849000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-51976000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-32612000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-42087000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2020Q3 us-gaap Inventory Write Down
InventoryWriteDown
5700000
CY2020Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
600000
CY2020Q4 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
500000

Files In Submission

Name View Source Status
0001564590-22-011525-index-headers.html Edgar Link pending
0001564590-22-011525-index.html Edgar Link pending
0001564590-22-011525.txt Edgar Link pending
0001564590-22-011525-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gwhjd53sdpst000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
txmd-10k_20211231.htm Edgar Link pending
txmd-10k_20211231_htm.xml Edgar Link completed
txmd-20211231.xsd Edgar Link pending
txmd-20211231_cal.xml Edgar Link unprocessable
txmd-20211231_def.xml Edgar Link unprocessable
txmd-20211231_lab.xml Edgar Link unprocessable
txmd-20211231_pre.xml Edgar Link unprocessable
txmd-ex1055_277.htm Edgar Link pending
txmd-ex231_10.htm Edgar Link pending
txmd-ex311_8.htm Edgar Link pending
txmd-ex312_9.htm Edgar Link pending
txmd-ex321_6.htm Edgar Link pending
txmd-ex322_7.htm Edgar Link pending